<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025337</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02417</org_study_id>
    <secondary_id>E3200</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <secondary_id>CDR0000068951</secondary_id>
    <nct_id>NCT00025337</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated</brief_title>
  <official_title>Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Randomized phase III trial to compare the effectiveness of combination chemotherapy with or&#xD;
      without bevacizumab in treating patients who have advanced or metastatic colorectal cancer&#xD;
      that has been previously treated. Drugs used in chemotherapy use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab&#xD;
      can locate tumor cells and either kill them or deliver tumor-killing substances to them&#xD;
      without harming normal cells. Combining monoclonal antibody therapy with combination&#xD;
      chemotherapy may kill more tumor cells. It is not yet known if bevacizumab is more effective&#xD;
      with or without combination chemotherapy in treating colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Compare the response, time to progression, and overall survival of patients with&#xD;
      previously treated advanced or metastatic colorectal adenocarcinoma treated with oxaliplatin,&#xD;
      leucovorin calcium, and fluorouracil with or without bevacizumab versus bevacizumab only.&#xD;
      (Arm III closed to accrual as of 03/11/2003).&#xD;
&#xD;
      II. Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to ECOG performance&#xD;
      status (0 vs 1 or 2), and prior radiotherapy (yes vs no). Patients are randomized to 1 of 3&#xD;
      treatment arms.&#xD;
&#xD;
      Arm I: Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on&#xD;
      day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV&#xD;
      over 22 hours on days 1 and 2.&#xD;
&#xD;
      Arm II: Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.&#xD;
&#xD;
      Arm III: Patients receive bevacizumab as in arm I. (Arm closed to accrual as of 03/11/2003).&#xD;
&#xD;
      Courses in all arms repeat every 2 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients who achieve a complete response may receive 2 additional&#xD;
      courses.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2001</start_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From the date of entry on study, assessed up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response defined using RECIST criteria</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From the date of entry on the study to the appearance of new metastatic lesions or objective tumor progression, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">880</enrollment>
  <condition>Adenocarcinoma of the Colon</condition>
  <condition>Adenocarcinoma of the Rectum</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage III Colon Cancer</condition>
  <condition>Stage III Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (oxaliplatin, leucovorin calcium, fluorouracil)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (bevacizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab as in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm III (bevacizumab)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm II (oxaliplatin, leucovorin calcium, fluorouracil)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm II (oxaliplatin, leucovorin calcium, fluorouracil)</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)</arm_group_label>
    <arm_group_label>Arm II (oxaliplatin, leucovorin calcium, fluorouracil)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
               -  Advanced or metastatic disease&#xD;
&#xD;
               -  Must have received a fluoropyrimidine-based regimen and an irinotecan-based&#xD;
                  regimen, either alone or in combination, for advanced disease&#xD;
&#xD;
               -  May have relapsed within 6 months of adjuvant therapy with fluorouracil (5-FU)&#xD;
                  (or combination 5-FU and irinotecan) and progressed after single-agent irinotecan&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No history of thrombotic or hemorrhagic disorders&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST no greater than 5 times ULN&#xD;
&#xD;
          -  INR no greater than 1.5&#xD;
&#xD;
          -  PTT no greater than ULN&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  Proteinuria less than 1+ (i.e., 0 or trace)&#xD;
&#xD;
          -  Protein less than 500 mg by 24-hour urine collection&#xD;
&#xD;
          -  Proteinuria secondary to ureteral stents allowed&#xD;
&#xD;
               -  No proteinuria secondary to nephropathy&#xD;
&#xD;
          -  Controlled hypertension (less than 150/100 mm Hg) allowed if on a stable&#xD;
             antihypertensive regimen&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No unstable angina within the past 3 months&#xD;
&#xD;
          -  No serious nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior bevacizumab&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  No prior oxaliplatin&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 28 days since prior major surgical procedure&#xD;
&#xD;
          -  At least 10 days since prior aspirin dose of more than 325 mg/day&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation except prophylactic anticoagulation of&#xD;
             venous access device&#xD;
&#xD;
          -  No concurrent antiplatelet agents (e.g., dipyridamole, ticlopidine, clopidogrel, or&#xD;
             cilostazol)&#xD;
&#xD;
          -  No concurrent oral cryotherapy on day 1 of oxaliplatin administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Giantonio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eastern Cooperative Oncology Group</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

